Autoimmune Disease Therapeutics Market to reach USD 116.81 billion by 2032 at a CAGR of 5.52%
The Autoimmune Disease Therapeutics Market has been growing steadily, driven by the rising prevalence of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. Estimates of the yearly increases in the overall worldwide incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively, according to the National Institutes of Health. This increasing prevalence has heightened the need for more effective and targeted treatment options, significantly advancing therapeutic approaches. Among these advancements, biologics and biosimilars have emerged as transformative solutions, offering more precise mechanisms of action compared to traditional treatments and improving patient outcomes significantly.